Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.
Signal Transduct Target Ther
; 5(1): 212, 2020 09 22.
Article
in English
| MEDLINE | ID: covidwho-786590
ABSTRACT
The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies (NMAbs). Scientists have screened neutralizing antibodies using the virus receptor-binding domain (RBD) as an antigen, indicating that RBD contains multiple conformational neutralizing epitopes, which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses. This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Severe Acute Respiratory Syndrome
/
Antibodies, Neutralizing
/
Pandemics
/
Spike Glycoprotein, Coronavirus
/
Antibodies, Monoclonal
/
Antibodies, Viral
Type of study:
Randomized controlled trials
Language:
English
Journal:
Signal Transduct Target Ther
Year:
2020
Document Type:
Article
Affiliation country:
S41392-020-00318-0
Similar
MEDLINE
...
LILACS
LIS